Excelsior Biopharma Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Joseph Chen
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | 3.8% |
| Management average tenure | no data |
| Board average tenure | 10.7yrs |
Recent management updates
Recent updates
Be Wary Of Excelsior Biopharma (GTSM:6496) And Its Returns On Capital
Apr 01
Is Excelsior Biopharma Inc. (GTSM:6496) An Attractive Dividend Stock?
Mar 11Is Excelsior Biopharma (GTSM:6496) Using Too Much Debt?
Feb 09Are Poor Financial Prospects Dragging Down Excelsior Biopharma Inc. (GTSM:6496 Stock?
Jan 11
Our Take On The Returns On Capital At Excelsior Biopharma (GTSM:6496)
Dec 22Here's Why Excelsior Biopharma's (GTSM:6496) Statutory Earnings Are Arguably Too Conservative
Nov 30CEO
Joseph Chen
no data
Tenure
Mr. Joseph Chen serves as Chairman, President and General Manager at Excelsior Biopharma Inc. and has also been a Director since June 16, 2003. Product Manager and Sales Managers of Bristol-Myers Squibb Pr...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | no data | no data | 3.78% NT$ 59.1m | |
| Representative Director & Administration Department Manager | 12.3yrs | no data | no data | |
| Representative Director | 9.7yrs | no data | 4.1% NT$ 64.2m | |
| Representative Director | 12.3yrs | no data | no data | |
| Director | 10yrs | no data | no data | |
| Director | no data | no data | no data | |
| Supervisor | 10.7yrs | no data | 0.48% NT$ 7.5m | |
| Independent Director | no data | no data | no data | |
| Independent Director | no data | no data | no data | |
| Independent Director | no data | no data | no data | |
| Director | no data | no data | no data |
10.7yrs
Average Tenure
Experienced Board: 6496's board of directors are seasoned and experienced ( 10.7 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/04 07:56 |
| End of Day Share Price | 2025/02/04 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Excelsior Biopharma Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hsiu Chi Lin | Masterlink Securities Corp. |